(NASDAQ: BPMC) Blueprint Medicines's forecast annual revenue growth rate of 43.84% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 39.22%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.52%.
Blueprint Medicines's revenue in 2024 is $249,380,000.On average, 9 Wall Street analysts forecast BPMC's revenue for 2024 to be $24,020,266,699, with the lowest BPMC revenue forecast at $22,763,718,733, and the highest BPMC revenue forecast at $25,999,233,306. On average, 9 Wall Street analysts forecast BPMC's revenue for 2025 to be $34,366,381,762, with the lowest BPMC revenue forecast at $30,862,914,657, and the highest BPMC revenue forecast at $37,853,806,005.
In 2026, BPMC is forecast to generate $45,586,649,097 in revenue, with the lowest revenue forecast at $37,496,209,391 and the highest revenue forecast at $54,239,568,683.